Sign In
Buy GLPG
$27.38
+0.0650 (+0.238%)
At Close: Jun 03, 2026
3 Great Reasons to Buy Gilead Sciences Stock
11:02am, Wednesday, 22'nd Apr 2020
Hint: None of them having anything to do with the biotech's coronavirus drug.
If You Invested $1,000 in Gilead Sciences' IPO, This Is How Much Money You'd Have Now
01:01pm, Sunday, 19'th Apr 2020
Hint: You'll need a couple of commas.
$101.90 Million in Sales Expected for GALAPAGOS NV/S (NASDAQ:GLPG) This Quarter
05:28am, Friday, 17'th Apr 2020
Equities analysts expect GALAPAGOS NV/S (NASDAQ:GLPG) to post $101.90 million in sales for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for GALAPAGOS NV/S’s earning
Analysts Have Conflicting Sentiments on These Healthcare Companies: Danaher (DHR), Theratechnologies (THTX) and Galapagos (GLPG)
05:38pm, Thursday, 16'th Apr 2020
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Danaher (DHR), Theratechnologies (THTX) and Galapagos (GLPG). Danaher
Galapagos and Ryvu Announce Research Collaboration
06:12am, Thursday, 16'th Apr 2020
Galapagos NV (Euronext: GLPG) (NASDAQ: GLPG) and Ryvu Therapeutics S.A. (WSE: RVU) today announced a collaboration focused on the discovery and development of novel small molecule drugs in inflammatio
Galapagos (GLPG) Receives a Hold from Morgan Stanley
03:26pm, Wednesday, 15'th Apr 2020
Morgan Stanley analyst Matthew Harrison maintained a Hold rating on Galapagos (GLPG) today and set a price target of $226.00. The company's shares closed
Comparing Akorn (NASDAQ:AKRX) & GALAPAGOS NV/S (NASDAQ:GLPG)
06:26am, Wednesday, 15'th Apr 2020
Akorn (NASDAQ:AKRX) and GALAPAGOS NV/S (NASDAQ:GLPG) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuati
Alliancebernstein L.P. Sells 13,110 Shares of GALAPAGOS NV/S (NASDAQ:GLPG)
09:22am, Monday, 13'th Apr 2020
Alliancebernstein L.P. reduced its position in shares of GALAPAGOS NV/S (NASDAQ:GLPG) by 46.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Com
Is Galapagos Stock a Buy?
12:09pm, Sunday, 12'th Apr 2020
Investors may want to own this biotech before its lead drug gets approved.
Gilead Heightens Inflammatory Disease Focus With Second Genome Microbiome Deal
11:47pm, Wednesday, 08'th Apr 2020
Gilead Sciences has signed an agreement with South San Francisco biotech Second Genome to use its microbiome drug development expertise to advance the
Gilead: Upside From Potential Coronavirus Treatment Could Dissipate
06:25pm, Wednesday, 08'th Apr 2020
In February, GILD divulged it was providing remdesivir to coronavirus patients on an emergency basis. GILD is up by double digits since then. The upside could d
Incyte details late-stage data on ruxolitinib cream for atopic dermatitis
06:55pm, Sunday, 05'th Apr 2020
Following up on its initial announcements in January and February, Incyte (NASDAQ:INCY) reports detailed results from two successful Phase 3 clinical trials, TRuE-AD1 and TRuE-AD2, evaluating a topica
Cubist Systematic Strategies LLC Has $1.17 Million Stock Position in GALAPAGOS NV/S (NASDAQ:GLPG)
10:18am, Saturday, 04'th Apr 2020
Cubist Systematic Strategies LLC lifted its position in shares of GALAPAGOS NV/S (NASDAQ:GLPG) by 172.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Co
Raymond James likes Amgen in premarket analyst action
12:06pm, Monday, 30'th Mar 2020
BioSig Technologies (NASDAQ:BSGM) initiated with Buy rating and $9 (75% upside) price target at Roth Capital.Amgen (NASDAQ:AMGN) upgraded to Outperform with a $255 (29% upside) price target at Raymond
Better Coronavirus Stock: Gilead Sciences or Regeneron Pharmaceuticals?
11:02am, Thursday, 19'th Mar 2020
If a safe and effective treatment for COVID-19 is close at hand, it will likely come from one of these two biotechs.
